Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tomeka vs Vernonia Amygdalina for COVID-19 in DRC
NCT04537585Unknown
- Start
- Nov 2020
- Primary completion
- Nov 2022
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Randomised, double-blind trial of vernonia amygdalina in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoint: Number of participants with treatment-TOMEKA® usage at 18 months. Status: unknown.
02
Drugs
vernonia amygdalina
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04537585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04537585.